Molecular mechanisms of cancer cachexia‑induced muscle atrophy (Review)
- Authors:
- Wei Yang
- Jianhui Huang
- Hui Wu
- Yuqing Wang
- Zhiyin Du
- Yuanbo Ling
- Weizhuo Wang
- Qian Wu
- Wenbin Gao
-
Affiliations: Department of Oncology, The Third Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518000, P.R. China, Department of Oncology, Lishui Municipal Central Hospital, Lishui, Zhejiang 323000, P.R. China, Department of Clinical Medicine, Anhui University of Science and Technology, Huainan, Anhui 232001, P.R. China - Published online on: October 16, 2020 https://doi.org/10.3892/mmr.2020.11608
- Pages: 4967-4980
-
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12:489–495. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Blum D, Stene GB, Solheim TS, Fayers P, Hjermstad MJ, Baracos VE, Fearon K, Strasser F and Kaasa S; Euro-Impact: Validation of the consensus-definition for cancer cachexia and evaluation of a classification model-a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol. 25:1635–1642. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ and Lindeman RD: Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 147:755–763. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Emery PW, Edwards RH, Rennie MJ, Souhami RL and Halliday D: Protein synthesis in muscle measured in vivo in cachectic patients with cancer. Br Med J (Clin Res Ed). 289:584–586. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Warnold I, Lundholm K and Schersten T: Energy balance and body composition in cancer patients. Cancer Res. 38:1801–1807. 1978.PubMed/NCBI | |
|
Chang VT, Xia Q and Kasimis B: The functional assessment of anorexia/cachexia therapy (FAACT) appetite scale in veteran cancer patients. J Support Oncol. 3:377–382. 2005.PubMed/NCBI | |
|
Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB and Baracos VE: Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 31:1539–1547. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO Jr, Engstrom PF, Ezdinli EZ, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 69:491–497. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
Dunne RF, Roussel B, Culakova E, Pandya C, Fleming FJ, Hensley B, Magnuson AM, Loh KP, Gilles M, Ramsdale E, et al: Characterizing cancer cachexia in the geriatric oncology population. J Geriatr Oncol. 10:415–419. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sadeghi M, Keshavarz-Fathi M, Baracos V, Arends J, Mahmoudi M and Rezaei N: Cancer cachexia: Diagnosis, assessment, and treatment. Crit Rev Oncol Hematol. 127:91–104. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tazi E and Errihani H: Treatment of cachexia in oncology. Indian J Palliat Care. 16:129–137. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL and Reid MB: TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 19:362–370. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris LG and Zimmers TA: JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 303:E410–421. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Braun TP, Zhu X, Szumowski M, Scott GD, Grossberg AJ, Levasseur PR, Graham K, Khan S, Damaraju S, Colmers WF, et al: Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J Exp Med. 208:2449–2463. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Judge SM, Wu CL, Beharry AW, Roberts BM, Ferreira LF, Kandarian SC and Judge AR: Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia. BMC Cancer. 14:9972014. View Article : Google Scholar : PubMed/NCBI | |
|
Schmitt TL, Martignoni ME, Bachmann J, Fechtner K, Friess H, Kinscherf R and Hildebrandt W: Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia. J Mol Med (Berl). 85:647–654. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Silva KA, Dong J, Dong Y, Dong Y, Schor N, Tweardy DJ, Zhang L and Mitch WE: Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem. 290:11177–11187. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Murton AJ, Maddocks M, Stephens FB, Marimuthu K, England R and Wilcock A: Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. Clin Lung Cancer. 18:e1–e11. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sugiyama M, Yamaki A, Furuya M, Inomata N, Minamitake Y, Ohsuye K and Kangawa K: Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice. Regul Pept. 178:21–28. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, Busquets S, Bonelli G, Lopez-Soriano FJ, Doglietto GB, et al: IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 291:R674–683. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yang J, Zhang Z, Zhang Y, Ni X, Zhang G, Cui X, Liu M, Xu C, Zhang Q, Zhu H, et al: ZIP4 promotes muscle wasting and cachexia in mice with orthotopic pancreatic tumors by stimulating RAB27B-regulated release of extracellular vesicles from cancer cells. Gastroenterology. 156:722–734.e6. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pin F, Minero VG, Penna F, Muscaritoli M, De Tullio R, Baccino FM and Costelli P: Interference with Ca2+-dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia. Front Physiol. 8:2132017. View Article : Google Scholar : PubMed/NCBI | |
|
Camperi A, Pin F, Costamagna D, Penna F, Menduina ML, Aversa Z, Zimmers T, Verzaro R, Fittipaldi R, Caretti G, et al: Vitamin D and VDR in cancer cachexia and muscle regeneration. Oncotarget. 8:21778–21793. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Marzetti E, Lorenzi M, Landi F, Picca A, Rosa F, Tanganelli F, Galli M, Doglietto GB, Pacelli F, Cesari M, et al: Altered mitochondrial quality control signaling in muscle of old gastric cancer patients with cachexia. Exp Gerontol. 87:92–99. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Williams A, Sun X, Fischer JE and Hasselgren PO: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 126:744–750. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Doyle A, Zhang G, Abdel Fattah EA, Eissa NT and Li YP: Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J. 25:99–110. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Furuno K and Goldberg AL: The activation of protein degradation in muscle by Ca2+ or muscle injury does not involve a lysosomal mechanism. Biochem J. 237:859–864. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Lecker SH, Solomon V, Mitch WE and Goldberg AL: Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr. 129 (Suppl 1):S227–S237. 1999. View Article : Google Scholar | |
|
White JP, Puppa MJ, Gao S, Sato S, Welle SL and Carson JA: Muscle mTORC1 suppression by IL-6 during cancer cachexia: A role for AMPK. Am J Physiol Endocrinol Metab. 304:E1042–E1052. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li YP, Schwartz RJ, Waddell ID, Holloway BR and Reid MB: Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J. 12:871–880. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Bohnert KR, Gallot YS, Sato S, Xiong G, Hindi SM and Kumar A: Inhibition of ER stress and unfolding protein response pathways causes skeletal muscle wasting during cancer cachexia. FASEB J. 30:3053–3068. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fontes-Oliveira CC, Busquets S, Toledo M, Penna F, Paz Aylwin M, Sirisi S, Silva AP, Orpí M, García A, Sette A, et al: Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency? Biochim Biophys Acta. 1830:2770–2778. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mondello P, Mian M, Aloisi C, Fama F, Mondello S and Pitini V: Cancer cachexia syndrome: Pathogenesis, diagnosis, and new therapeutic options. Nutr Cancer. 67:12–26. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hershko A and Ciechanover A: The ubiquitin system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Hershko A and Ciechanover A: Mechanisms of intracellular protein breakdown. Annu Rev Biochem. 51:335–364. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Haas AL and Rose IA: The mechanism of ubiquitin activating enzyme. A kinetic and equilibrium analysis. J Biol Chem. 257:10329–10337. 1982.PubMed/NCBI | |
|
Hershko A, Heller H, Elias S and Ciechanover A: Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem. 258:8206–8214. 1983.PubMed/NCBI | |
|
Hershko A: The ubiquitin pathway for protein degradation. Trends Biochem Sci. 16:265–268. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Reiss Y, Heller H and Hershko A: Binding sites of ubiquitin-protein ligase. Binding of ubiquitin-protein conjugates and of ubiquitin-carrier protein. J Biol Chem. 264:10378–10383. 1989.PubMed/NCBI | |
|
Voges D, Zwickl P and Baumeister W: The 26S proteasome: A molecular machine designed for controlled proteolysis. Annu Rev Biochem. 68:1015–1068. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Glickman MH and Ciechanover A: The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev. 82:373–428. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Rom O and Reznick AZ: The role of E3 ubiquitin-ligases MuRF-1 and MAFbx in loss of skeletal muscle mass. Free Radic Biol Med. 98:218–230. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ and Shoelson SE: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 119:285–298. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Moylan JS, Chambers MA, Smith J and Reid MB: Interleukin-1 stimulates catabolism in C2C12 myotubes. Am J Physiol Cell Physiol. 297:C706–C714. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
McClung JM, Judge AR, Powers SK and Yan Z: p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol. 298:C542–C549. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kaisari S, Rom O, Aizenbud D and Reznick AZ: Involvement of NF-κB and muscle specific E3 ubiquitin ligase MuRF1 in cigarette smoke-induced catabolism in C2 myotubes. Adv Exp Med Biol. 788:7–17. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Patel HJ and Patel BM: TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci. 170:56–63. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Parajuli P, Kumar S, Loumaye A, Singh P, Eragamreddy S, Nguyen TL, Ozkan S, Razzaque MS, Prunier C, Thissen JP and Atfi A: Twist1 activation in muscle progenitor cells causes muscle loss akin to cancer cachexia. Dev Cell. 45:712–725.e6. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Fry CS, Nayeem SZ, Dillon EL, Sarkar PS, Tumurbaatar B, Urban RJ, Wright TJ, Sheffield-Moore M, Tilton RG and Choudhary S: Glucocorticoids increase skeletal muscle NF-κB inducing kinase (NIK): Links to muscle atrophy. Physiol Rep. 4:2016. View Article : Google Scholar | |
|
Gallot YS, Durieux AC, Castells J, Desgeorges MM, Vernus B, Plantureux L, Rémond D, Jahnke VE, Lefai E, Dardevet D, et al: Myostatin gene inactivation prevents skeletal muscle wasting in cancer. Cancer Res. 74:7344–7356. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bédard N, Jammoul S, Moore T, Wykes L, Hallauer PL, Hastings KE, Stretch C, Baracos V, Chevalier S, Plourde M, et al: Inactivation of the ubiquitin-specific protease 19 deubiquitinating enzyme protects against muscle wasting. FASEB J. 29:3889–3898. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lee H, Lee SJ, Bae GU, Baek NI and Ryu JH: Canadine from corydalis turtschaninovii stimulates myoblast differentiation and protects against myotube atrophy. Int J Mol Sci. 18:27482017. View Article : Google Scholar | |
|
Chen L, Yang Q, Zhang H, Wan L, Xin B, Cao Y, Zhang J and Guo C: Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway. J Ethnopharmacol. 260:1130662020. View Article : Google Scholar : PubMed/NCBI | |
|
Chong SW, Nguyet LM, Jiang YJ and Korzh V: The chemokine Sdf-1 and its receptor Cxcr4 are required for formation of muscle in zebrafish. BMC Dev Biol. 7:542007. View Article : Google Scholar : PubMed/NCBI | |
|
Melchionna R, Di Carlo A, De Mori R, Cappuzzello C, Barberi L, Musarò A, Cencioni C, Fujii N, Tamamura H, Crescenzi M, et al: Induction of myogenic differentiation by SDF-1 via CXCR4 and CXCR7 receptors. Muscle Nerve. 41:828–835. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bobadilla M, Sainz N, Abizanda G, Orbe J, Rodriguez JA, Páramo JA, Prósper F and Pérez-Ruiz A: The CXCR4/SDF1 axis improves muscle regeneration through MMP-10 activity. Stem Cells Dev. 23:1417–1427. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Martinelli GB, Olivari D, Re Cecconi AD, Talamini L, Ottoboni L, Lecker SH, Stretch C, Baracos VE, Bathe OF, Resovi A, et al: Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia. Oncogene. 35:6212–6222. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Winbanks CE, Murphy KT, Bernardo BC, Qian H, Liu Y, Sepulveda PV, Beyer C, Hagg A, Thomson RE, Chen JL, et al: Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. Sci Transl Med. 8:348ra3982016. View Article : Google Scholar | |
|
Stephens NA, Gallagher IJ, Rooyackers O, Skipworth RJ, Tan BH, Marstrand T, Ross JA, Guttridge DC, Lundell L, Fearon KC and Timmons JA: Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. Genome Med. 2:12010. View Article : Google Scholar : PubMed/NCBI | |
|
Eskiler GG, Bezdegumeli E, Ozman Z, Ozkan AD, Bilir C, Kucukakca BN, Ince MN, Men AY, Aktas O, Horoz YE, et al: IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia. Bratisl Lek Listy. 66:819–826. 2019.PubMed/NCBI | |
|
Pin F, Barreto R, Kitase Y, Mitra S, Erne CE, Novinger LJ, Zimmers TA, Couch ME, Bonewald LF and Bonetto A: Growth of ovarian cancer xenografts causes loss of muscle and bone mass: A new model for the study of cancer cachexia. J Cachexia Sarcopenia Muscle. 9:685–700. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Grabiec AM, Korchynskyi O, Tak PP and Reedquist KA: Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis. 71:424–431. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, Qi Y and Du J: Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF β/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One. 7:e351442012. View Article : Google Scholar : PubMed/NCBI | |
|
Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T and Kishimoto T: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 250:607–610. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Iwase S, Murakami T, Saito Y and Nakagawa K: Steep elevation of blood interleukin-6 (IL-6) associated only with late stages of cachexia in cancer patients. Eur Cytokine Netw. 15:312–316. 2004.PubMed/NCBI | |
|
Fujimoto-Ouchi K, Onuma E, Shirane M, Mori K and Tanaka Y: Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. Cancer Chemother Pharmacol. 59:807–815. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
White JP, Baltgalvis KA, Puppa MJ, Sato S, Baynes JW and Carson JA: Muscle oxidative capacity during IL-6-dependent cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 300:R201–R211. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Op den Kamp CM, Gosker HR, Lagarde S, Tan DY, Snepvangers FJ, Dingemans AM, Langen RC and Schols AM: Preserved muscle oxidative metabolic phenotype in newly diagnosed non-small cell lung cancer cachexia. J Cachexia Sarcopenia Muscle. 6:164–173. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Siddiqui RA and Williams JF: Tentative identification of the toxohormones of cancer cachexia: Roles of vasopressin, prostaglandin E2 and cachectin-TNF. Biochem Int. 20:787–797. 1990.PubMed/NCBI | |
|
Llovera M, García-Martínez C, López-Soriano J, Carbó N, Agell N, López-Soriano FJ and Argiles JM: Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol. 142:183–189. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Powrozek T, Mlak R, Brzozowska A, Mazurek M, Golebiowski P and Malecka-Massalska T: Relationship between TNF-α −1031T/C gene polymorphism, plasma level of TNF-α, and risk of cachexia in head and neck cancer patients. J Cancer Res Clin Oncol. 144:1423–1434. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Llovera M, García-Martínez C, Agell N, López-Soriano FJ and Argilés JM: TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun. 230:238–241. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuyama T, Ishikawa T, Okayama T, Oka K, Adachi S, Mizushima K, Kimura R, Okajima M, Sakai H, Sakamoto N, et al: Tumor inoculation site affects the development of cancer cachexia and muscle wasting. Int J Cancer. 137:2558–2565. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mu X, Agarwal R, March D, Rothenberg A, Voigt C, Tebbets J, Huard J and Weiss K: Notch signaling mediates skeletal muscle atrophy in cancer cachexia caused by osteosarcoma. Sarcoma. 2016:37581622016. View Article : Google Scholar : PubMed/NCBI | |
|
Cannon T, Shores C, Yin X, Dahlman J, Guttridge D, Lai V, George J, Buzkova P and Couch M: Immunocompetent murine model of cancer cachexia for head and neck squamous cell carcinoma. Head Neck. 30:320–326. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mi L, Lin J, Zheng H, Xu X, Zhang J and Zhang D: Bacterial translocation contributes to cachexia from locally advanced gastric cancer. Hepatogastroenterology. 59:2348–2351. 2012.PubMed/NCBI | |
|
Kumar S, Kishimoto H, Chua HL, Badve S, Miller KD, Bigsby RM and Nakshatri H: Interleukin-1 alpha promotes tumor growth and cachexia in MCF-7 ×enograft model of breast cancer. Am J Pathol. 163:2531–2541. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng R, Huang S, Zhu J, Lin W, Xu H and Zheng X: Leucine attenuates muscle atrophy and autophagosome formation by activating PI3K/AKT/mTOR signaling pathway in rotator cuff tears. Cell Tissue Res. 378:113–125. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee S, Kim MB, Kim C and Hwang JK: Whole grain cereal attenuates obesity-induced muscle atrophy by activating the PI3K/Akt pathway in obese C57BL/6N mice. Food Sci Biotechnol. 27:159–168. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 10:307–318. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang BH, Aoki M, Zheng JZ, Li J and Vogt PK: Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc Natl Acad Sci USA. 96:2077–2081. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Price DJ, Grove JR, Calvo V, Avruch J and Bierer BE: Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science. 257:973–977. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Chung J, Kuo CJ, Crabtree GR and Blenis J: Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 69:1227–1236. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Lin TA, Kong X, Saltiel AR, Blackshear PJ and Lawrence JC Jr: Control of PHAS-I by insulin in 3T3-L1 adipocytes. Synthesis, degradation, and phosphorylation by a rapamycin-sensitive and mitogen-activated protein kinase-independent pathway. J Biol Chem. 270:18531–18538. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Graves LM, Bornfeldt KE, Argast GM, Krebs EG, Kong X, Lin TA and Lawrence JC Jr: cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells. Proc Natl Acad Sci USA. 92:7222–7226. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD and Glass D: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 14:395–403. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH and Goldberg AL: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 117:399–412. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Manne ND, Lima M, Enos RT, Wehner P, Carson JA and Blough E: Altered cardiac muscle mTOR regulation during the progression of cancer cachexia in the ApcMin/+ mouse. Int J Oncol. 42:2134–2140. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ge Y, Wu AL, Warnes C, Liu J, Zhang C, Kawasome H, Terada N, Boppart MD, Schoenherr CJ and Chen J: mTOR regulates skeletal muscle regeneration in vivo through kinase-dependent and kinase-independent mechanisms. Am J Physiol Cell Physiol. 297:C1434–C1444. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zimmers TA, Fishel ML and Bonetto A: STAT3 in the systemic inflammation of cancer cachexia. Semin Cell Dev Biol. 54:28–41. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG and Zimmers TA: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 6:e225382011. View Article : Google Scholar : PubMed/NCBI | |
|
Ma JF, Sanchez BJ, Hall DT, Tremblay AK, Di Marco S and Gallouzi IE: STAT3 promotes IFNγ/TNFα-induced muscle wasting in an NF-κB-dependent and IL-6-independent manner. EMBO Mol Med. 9:622–637. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell. 109 (Suppl 1):S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Hayden MS and Ghosh S: NF-kappaB in immunobiology. Cell Res. 21:223–244. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Thoma A and Lightfoot AP: NF-kB and inflammatory cytokine signalling: Role in skeletal muscle atrophy. Adv Exp Med Biol. 1088:267–279. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Di Marco S, Mazroui R, Dallaire P, Chittur S, Tenenbaum SA, Radzioch D, Marette A and Gallouzi IE: NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol Cell Biol. 25:6533–6545. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Cuenda A and Rousseau S: p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 1773:1358–1375. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Won KJ, Lee HM, Hwang BY, Bae YM, Choi WS, Song H, Lim KW, Lee CK and Kim B: p38 MAPK participates in muscle-specific RING finger 1-mediated atrophy in cast-immobilized rat gastrocnemius muscle. Korean J Physiol Pharmacol. 13:491–496. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ryu Y, Lee D, Jung SH, Lee KJ, Jin H, Kim SJ, Lee HM, Kim B and Won KJ: Sabinene prevents skeletal muscle atrophy by inhibiting the MAPK-MuRF-1 pathway in rats. Int J Mol Sci. 20:49552019. View Article : Google Scholar | |
|
Belova SP, Mochalova EP, Kostrominova TY, Shenkman BS and Nemirovskaya TL: P38α-MAPK signaling inhibition attenuates soleus atrophy during early stages of muscle unloading. Int J Mol Sci. 21:27562020. View Article : Google Scholar | |
|
Girven M, Dugdale HF, Owens DJ, Hughes DC, Stewart CE and Sharples AP: l-glutamine improves skeletal muscle cell differentiation and prevents myotube atrophy after cytokine (TNF-α) stress via reduced p38 MAPK signal transduction. J Cell Physiol. 231:2720–2732. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Morales MG, Olguin H, Di Capua G, Brandan E, Simon F and Cabello-Verrugio C: Endotoxin-induced skeletal muscle wasting is prevented by angiotensin-(1–7) through a p38 MAPK-dependent mechanism. Clin Sci (Lond). 129:461–476. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
O'Neill BT, Bhardwaj G, Penniman CM, Krumpoch MT, Suarez Beltran PA, Klaus K, Poro K, Li M, Pan H, Dreyfuss JM, et al: FoxO transcription factors are critical regulators of diabetes-related muscle atrophy. Diabetes. 68:556–570. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu CM, Yang Z, Liu CW, Wang R, Tien P, Dale R and Sun LQ: Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 14:945–952. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Blackwell TA, Cervenka I, Khatri B, Brown JL, Rosa-Caldwell ME, Lee DE, Perry RA Jr, Brown LA, Haynie WS, Wiggs MP, et al: Transcriptomic analysis of the development of skeletal muscle atrophy in cancer-cachexia in tumor-bearing mice. Physiol Genomics. 50:1071–1082. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Marchildon F, Lamarche E, Lala-Tabbert N, St-Louis C and Wiper-Bergeron N: Expression of CCAAT/enhancer binding protein beta in muscle satellite cells inhibits myogenesis in cancer cachexia. PLoS One. 10:e01455832015. View Article : Google Scholar : PubMed/NCBI | |
|
Freire PP, Fernandez GJ, Cury SS, de Moraes D, Oliveira JS, de Oliveira G, Dal-Pai-Silva M, Dos Reis PP and Carvalho RF: The pathway to cancer cachexia: MicroRNA-regulated networks in muscle wasting based on integrative meta-analysis. Int J Mol Sci. 20:2019. View Article : Google Scholar | |
|
Lee DE, Brown JL, Rosa-Caldwell ME, Blackwell TA, Perry RA Jr, Brown LA, Khatri B, Seo D, Bottje WG, Washington TA, et al: Cancer cachexia-induced muscle atrophy: Evidence for alterations in microRNAs important for muscle size. Physiol Genomics. 49:253–260. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sandri M: Autophagy in health and disease. 3. Involvement of autophagy in muscle atrophy. Am J Physiol Cell Physiol. 298:C1291–C1297. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bargiela A, Cerro-Herreros E, Fernandez-Costa JM, Vilchez JJ, Llamusi B and Artero R: Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila model. Dis Model Mech. 8:679–690. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pettersen K, Andersen S, Degen S, Tadini V, Grosjean J, Hatakeyama S, Tesfahun AN, Moestue S, Kim J, Nonstad U, et al: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Sci Rep. 7:20462017. View Article : Google Scholar : PubMed/NCBI | |
|
Penna F, Ballarò R, Martinez-Cristobal P, Sala D, Sebastian D, Busquets S, Muscaritoli M, Argilés JM, Costelli P and Zorzano A: Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J Mol Biol. 431:2674–2686. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pettersen K, Andersen S, van der Veen A, Nonstad U, Hatakeyama S, Lambert C, Lach-Trifilieff E, Moestue S, Kim J, Grønberg BH, et al: Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia. J Cachexia Sarcopenia Muscle. 11:195–207. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Mirza KA and Tisdale MJ: Role of Ca2+ in proteolysis-inducing factor (PIF)-induced atrophy of skeletal muscle. Cell Signal. 24:2118–2122. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kozutsumi Y, Segal M, Normington K, Gething MJ and Sambrook J: The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature. 332:462–464. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Bohnert KR, McMillan JD and Kumar A: Emerging roles of ER stress and unfolded protein response pathways in skeletal muscle health and disease. J Cell Physiol. 233:67–78. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu CY, Schröder M and Kaufman RJ: Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. J Biol Chem. 275:24881–24885. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Bertolotti A, Zhang Y, Hendershot LM, Harding HP and Ron D: Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol. 2:326–332. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida H, Matsui T, Yamamoto A, Okada T and Mori K: XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 107:881–891. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Shen J, Chen X, Hendershot L and Prywes R: ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev Cell. 3:99–111. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Roy A and Kumar A: ER stress and unfolded protein response in cancer cachexia. Cancers (Basel). 11:19292019. View Article : Google Scholar | |
|
Wu J and Kaufman RJ: From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death Differ. 13:374–384. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Isaac ST, Tan TC and Polly P: Endoplasmic reticulum stress, calcium dysregulation and altered protein translation: Intersection of processes that contribute to cancer cachexia induced skeletal muscle wasting. Curr Drug Targets. 17:1140–1146. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Barreiro E, Salazar-Degracia A, Sancho-Muñoz A and Gea J: Endoplasmic reticulum stress and unfolded protein response profile in quadriceps of sarcopenic patients with respiratory diseases. J Cell Physiol. 234:11315–11329. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tam AB, Mercado EL, Hoffmann A and Niwa M: ER stress activates NF-κB by integrating functions of basal IKK activity, IRE1 and PERK. PLoS One. 7:e450782012. View Article : Google Scholar : PubMed/NCBI | |
|
White JP, Puppa MJ, Sato S, Gao S, Price RL, Baynes JW, Kostek MC, Matesic LE and Carson JA: IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse. Skelet Muscle. 2:142012. View Article : Google Scholar : PubMed/NCBI | |
|
Brown JL, Rosa-Caldwell ME, Lee DE, Blackwell TA, Brown LA, Perry RA, Haynie WS, Hardee JP, Carson JA, Wiggs MP, et al: Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice. J Cachexia Sarcopenia Muscle. 8:926–938. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
VanderVeen BN, Fix DK and Carson JA: Disrupted skeletal muscle mitochondrial dynamics, mitophagy, and biogenesis during cancer cachexia: A role for inflammation. Oxid Med Cell Longev. 2017:32920872017. View Article : Google Scholar : PubMed/NCBI | |
|
van der Ende M, Grefte S, Plas R, Meijerink J, Witkamp RF, Keijer J and van Norren K: Mitochondrial dynamics in cancer-induced cachexia. Biochim Biophys Acta Rev Cancer. 1870:137–150. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dave DT and Patel BM: Mitochondrial metabolism in cancer cachexia: Novel drug target. Curr Drug Metab. 20:1141–1153. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Neyroud D, Nosacka RL, Judge AR and Hepple RT: Colon 26 adenocarcinoma (C26)-induced cancer cachexia impairs skeletal muscle mitochondrial function and content. J Muscle Res Cell Motil. 40:59–65. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pin F, Novinger LJ, Huot JR, Harris RA, Couch ME, O'Connell TM and Bonetto A: PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB J. 33:7778–7790. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Du Bois P, Pablo Tortola C, Lodka D, Kny M, Schmidt F, Song K, Schmidt S, Bassel-Duby R, Olson EN and Fielitz J: Angiotensin II induces skeletal muscle atrophy by activating TFEB-mediated MuRF1 expression. Circ Res. 117:424–436. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kadoguchi T, Kinugawa S, Takada S, Fukushima A, Furihata T, Homma T, Masaki Y, Mizushima W, Nishikawa M, Takahashi M, et al: Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle. Exp Physiol. 100:312–322. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Cisternas F, Morales MG, Meneses C, Simon F, Brandan E, Abrigo J, Vazquez Y and Cabello-Verrugio C: Angiotensin-(1–7) decreases skeletal muscle atrophy induced by angiotensin II through a Mas receptor-dependent mechanism. Clin Sci (Lond). 128:307–319. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida T, Tabony AM, Galvez S, Mitch WE, Higashi Y, Sukhanov S and Delafontaine P: Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: Potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol. 45:2322–2332. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Penafuerte CA, Gagnon B, Sirois J, Murphy J, MacDonald N and Tremblay ML: Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. Br J Cancer. 114:680–687. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cai X, Zhu C, Xu Y, Jing Y, Yuan Y, Wang L, Wang S, Zhu X, Gao P, Zhang Y, et al: Alpha-ketoglutarate promotes skeletal muscle hypertrophy and protein synthesis through Akt/mTOR signaling pathways. Sci Rep. 6:268022016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu D, Qiao X, Ge Z, Shang Y, Li Y, Wang W, Chen M, Si S and Chen SZ: IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway. Skelet Muscle. 9:82019. View Article : Google Scholar : PubMed/NCBI | |
|
Bae T, Jang J, Lee H, Song J, Chae S, Park M, Son CG, Yoon S and Yoon Y: Paeonia lactiflora root extract suppresses cancer cachexia by down-regulating muscular NF-κB signalling and muscle-specific E3 ubiquitin ligases in cancer-bearing mice. J Ethnopharmacol. 246:1122222020. View Article : Google Scholar : PubMed/NCBI | |
|
Levolger S, Wiemer EAC, van Vugt JLA, Huisman SA, van Vledder MG, van Damme-van Engel S, Ambagtsheer G, IJzermans JNM and de Bruin RWF: Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting. Sci Rep. 9:98262019. View Article : Google Scholar : PubMed/NCBI | |
|
An JM, Kang EA, Han YM, Oh JY, Lee DY, Choi SH, Kim DH and Hahm KB: Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia. J Clin Biochem Nutr. 65:109–117. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Li L, Zou J, Zhou T, Wang B, Sun H and Yu S: Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis. BMC Complement Altern Med. 19:2672019. View Article : Google Scholar : PubMed/NCBI | |
|
Terawaki K, Sawada Y, Kashiwase Y, Hashimoto H, Yoshimura M, Suzuki M, Miyano K, Sudo Y, Shiraishi S, Higami Y, et al: New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line. Am J Physiol Endocrinol Metab. 306:E373–E387. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xi QL, Zhang B, Jiang Y, Zhang HS, Meng QY, Chen Y, Han YS, Zhuang QL, Han J, Wang HY, et al: Mitofusin-2 prevents skeletal muscle wasting in cancer cachexia. Oncol Lett. 12:4013–4020. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Toledo M, Busquets S, Penna F, Zhou X, Marmonti E, Betancourt A, Massa D, López-Soriano FJ, Han HQ and Argilés JM: Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and beta-2 agonist. Int J Cancer. 138:2021–2029. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Khamoui AV, Park BS, Kim DH, Yeh MC, Oh SL, Elam ML, Jo E, Arjmandi BH, Salazar G, Grant SC, et al: Aerobic and resistance training dependent skeletal muscle plasticity in the colon-26 murine model of cancer cachexia. Metabolism. 65:685–698. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tanaka M, Sugimoto K, Fujimoto T, Xie K, Takahashi T, Akasaka H, Kurinami H, Yasunobe Y, Matsumoto T, Fujino H and Rakugi H: Preventive effects of low-intensity exercise on cancer cachexia-induced muscle atrophy. FASEB J. 33:7852–7862. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Han X, Ouyang B, Wu Z, Yu H, Wang Y, Liu G and Ji X: Chinese herbal medicine Baoyuan Jiedu decoction inhibited muscle atrophy of cancer cachexia through Atrogin-l and MuRF-1. Evid Based Complement Alternat Med. 2017:62683782017.PubMed/NCBI | |
|
Sun R, Zhang S, Hu W, Lu X, Lou N, Yang Z, Chen S, Zhang X and Yang H: Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPbeta-regulated atrogin1 expression in cancer cachexia. Am J Physiol Cell Physiol. 311:C101–C115. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuang P, Zhang J, Wang Y, Zhang M, Song L, Lu Z, Zhang L, Zhang F, Wang J, Zhang Y, et al: Reversal of muscle atrophy by Zhimu and Huangbai herb pair via activation of IGF-1/Akt and autophagy signal in cancer cachexia. Support Care Cancer. 24:1189–1198. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen JM, Yang TT, Cheng TS, Hsiao TF, Chang PM, Leu JY, Wang FS, Hsu SL, Huang CF and Lai JM: Modified Sijunzi decoction can alleviate cisplatin-induced toxicity and prolong the survival time of cachectic mice by recovering muscle atrophy. J Ethnopharmacol. 233:47–55. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Molanouri Shamsi M, Chekachak S, Soudi S, Quinn LS, Ranjbar K, Chenari J, Yazdi MH and Mahdavi M: Combined effect of aerobic interval training and selenium nanoparticles on expression of IL-15 and IL-10/TNF-α ratio in skeletal muscle of 4T1 breast cancer mice with cachexia. Cytokine. 90:100–108. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Salazar-Degracia A, Busquets S, Argilés JM, Bargalló-Gispert N, López-Soriano FJ and Barreiro E: Effects of the beta2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia. Biochimie. 149:79–91. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pretto F, Ghilardi C, Moschetta M, Bassi A, Rovida A, Scarlato V, Talamini L, Fiordaliso F, Bisighini C, Damia G, et al: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. Oncotarget. 6:3043–3054. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Miao C, Lv Y, Zhang W, Chai X, Feng L, Fang Y, Liu X and Zhang X: Pyrrolidine dithiocarbamate (PDTC) attenuates cancer cachexia by affecting muscle atrophy and fat lipolysis. Front Pharmacol. 8:9152017. View Article : Google Scholar : PubMed/NCBI | |
|
Kadoguchi T, Takada S, Yokota T, Furihata T, Matsumoto J, Tsuda M, Mizushima W, Fukushima A, Okita K and Kinugawa S: Deletion of NAD(P)H oxidase 2 prevents angiotensin II-induced skeletal muscle atrophy. Biomed Res Int. 2018:31949172018. View Article : Google Scholar : PubMed/NCBI | |
|
Bosaeus I: Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer. 16:447–451. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Amano K, Morita T, Miyamoto J, Uno T, Katayama H and Tatara R: Perception of need for nutritional support in advanced cancer patients with cachexia: A survey in palliative care settings. Support Care Cancer. 26:2793–2799. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
McClement S: Cancer anorexia-cachexia syndrome: Psychological effect on the patient and family. J Wound Ostomy Continence Nurs. 32:264–268. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang WL, Li N, Shen Q, Fan M, Guo XD, Zhang XW, Zhang Z and Liu X: Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I. Acta Pharmacol Sin. 41:237–248. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kang HJ, Jeong MK, Park SJ, Jun HJ and Yoo HS: Efficacy and safety of Yukgunja-Tang for treating anorexia in patients with cancer: The protocol for a pilot, randomized, controlled trial. Medicine (Baltimore). 98:e169502019. View Article : Google Scholar : PubMed/NCBI |
